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dynamic incremental cost-effectiveness ratio (ICER), at the time of market entry 
and by year thereafter. While experts were not aware of any existing guidelines, 
the predominant view was that although using the brand price for the studied drug 
would be a conservative approach, it is reasonable to account for price reductions 
after patent expiration for all drugs considered. ConClusions: Drug price vari-
ations may introduce a source of uncertainty in CEA, as both timing of entry and 
level of generic drug pricing are unknown. There is currently no consensus on how 
this should be considered. Failure to incorporate generic drug entry in CEA is likely 
to yield overestimates of ICER for treatments used over long-term.
PRM30
EstiMating Costs in a Cost-EffECtivEnEss analysis: adhEREnCE to hta 
guidanCE
Mauskopf J.A.1, Mitchell S.E.2, Samuel M.2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2RTI Health Solutions, Manchester, UK
objeCtives: Since the results of a cost-effectiveness analysis (CEA) are generally 
sensitive to the input cost parameter values selected for difference disease-related 
outcomes a systematic approach should be used to derive these estimates as sug-
gested in HTA guidance. To determine the extent to which a systematic approach 
was used to select disease-related cost estimates for inclusion in CEAs for new 
hepatitis C treatments. Methods: A systematic literature review of primary cost-
ing studies and of the cost data used in published CEAs was performed for differ-
ent stages of liver disease for those with chronic hepatitis C infection. The process 
described in the cost-effectiveness analyses by which they selected the input 
base-case cost values as well as the ranges used in the sensitivity analyses was 
reviewed to determine whether or not a systematic approach was used to identify 
primary cost studies and whether or not the a rationale was supplied for the val-
ues selected. Results: The hepatitis C systematic review focused on US costs and 
cost-effectiveness analyses. In most of the hepatitis C cost-effectiveness analyses, 
the cost estimates used were either taken directly or derived from recent primary 
cost studies. However, a systematic review was not generally used to identify the 
recent primary cost studies. In addition, the method used to adapt the data from 
the selected studies for use in the CEA was either not explained and/or appeared to 
be incorrect in some of the CEAs. In most of the CEAs, sensitivity analyses assumed 
arbitrary ranges for the cost estimates (for example, plus or minus 50%) rather than 
using ranges from alternative cost studies. ConClusions: Very little detail is pro-
vided in published CEAs about the methods used to identify primary disease-related 
cost studies and a rationale for selection of the costs is generally not provided.
PRM31
idEntifying thE BRoadER valuE of vaCCinEs in low and MiddlE inCoME 
CountRiEs
Van der Putten I.M.1, Hiligsmann M.1, Paulus A.T.G.1, Hutubessy R.2, Evers S.M.1
1Maastricht University, Maastricht, The Netherlands, 2World Health Organization, Geneva, 
Switzerland
objeCtives: Current economic evaluations of vaccine immunization strategies 
mainly concentrate on immediate health gains (measured in metrics such as 
QALYs or DALYs) and household cost savings. Vaccine immunization strategies, 
however, often take place within a broader societal context. In order to finan-
cially sustain these strategies, economic evaluations should not only encompass 
immediate health gains and household costs but also the ‘broader value of vac-
cines’. This study aims to identify the relevance of information with regard to 
the broader value of vaccines for decision makers in low and middle income 
countries. Methods: Several methods were used to identify the broader value 
of vaccines including a literature review, a survey, interviews and consultations 
with experts. The long-term effects of those who were vaccinated and the effects 
experienced by society as a whole, including non-vaccinated community mem-
bers, were included in a framework. Results: In total, twenty broader values 
in five different domains were identified. The first domain included long-term 
productivity gains. These gains refer to the individual long-term productivity due 
to better physical and mental health as well as to the economic consequences of 
decisions made by households due to improved child survival. The second domain 
consists of ecological values which are related to the decline of prevalence and 
incidence of vaccine related diseases. The third domain encompasses different 
types of equity considerations. The fourth domain includes the impact of vaccine 
strategies on other health interventions. Finally, the fifth domain includes macro-
economic effects, such as the impact of vaccine immunization strategies on GDP 
tax revenues and overall government savings. ConClusions: Several broader 
economic values outside the health care sector were identified. These results 
provide the input for the incorporation of these values in economic evaluations. 
Further research is needed to identify the most important broader values for 
national decision makers.
PRM32
PRoPosal foR a CoMPREhEnsivE dEfinition of BudgEt iMPaCt analysis
Bierbaum M.
Friedrich-Alexander-Universität Erlangen-Nürnberg, Nuremberg, Germany
objeCtives: To our knowledge in most articles BIA is only defined as what it does. 
Some authors have tried to define it by comparing it to cost effectiveness analysis. But 
still there is no common stand-alone definition of the term Budget Impact Analysis 
available. Our aim is to provide such a definition. Methods: In the course of a PhD 
thesis we conducted a systematic literature review in order to identify methodo-
logical articles regarding budget impact analyses. We searched pudmed and seven 
other databases to identify relevant articles. From the eligible articles the different 
understandings and definitions of BIA were extracted and synthesized into a compre-
hensive definition. Results: Our search delivered 223 articles from which 28 met our 
inclusion criteria. 15 different approaches to describe BIAs were identified. Over the 
years (2001 to today) there was a constant improvement and increase of complexity 
in the descriptions. Nevertheless most of the late definitions are based on the work of 
set appears reasonably valid for research, particularly following accreditation. The 
dataset may be a suitable alternative to collecting MR data manually within a trial, 
although caution should be exercised with earlier data. Further work is ongoing to 
establish the nature of the missing data and the implications for cost differences.
PRM27
Can using a REsouRCE usE log in an EConoMiC Evaluation alongsidE 
a RandoMisEd ContRollEd tRial REduCE thE aMount of RECall Bias?
Noble S., Tudge I., Wylde V., Lenguerrand E., Marques E.M.
University of Bristol, Bristol, UK
objeCtives: To determine whether giving patients a resource use log (RUL) at 
hospital discharge reduces recall bias in a follow-up resource use questionnaire 
(RUQ). Methods: Within the APEX randomised controlled trials (RCTs), 86 patients 
undergoing joint replacement were randomised to receive or not receive an RUL at 
hospital discharge (The RUL trial). A postal RUQ was then administered to all par-
ticipants at 3-months after surgery. Resource use data (visits to GPs, GP home visits 
and telephone calls; GP practice nurse visits and telephone calls; and prescribed 
medication) in relation to the patient’s joint replacement were extracted from GP 
records from hospital discharge until completion of the 3-month RUQ by a blinded 
researcher. Data from both sources were coded into use of resource and number 
of contacts. For each resource use category, descriptive statistics were calculated 
by data source and RUL trial arm. Kappa statistics and Concordance Correlation 
Coefficients (CCC) were calculated as appropriate. Results: GPs were contacted 
for 67/86 patients originally randomised to receive or not receive an RUL (one had 
surgery delayed, 3 died, 5 withdrew, 6 had GP practices outside of area, 4 did not 
complete the 3-month RUQ). Information was then extracted for 66/67 patients. 
There was evidence of improved recall in favour of the RUL arm in relation to visiting 
a GP (Kappa= 0.5312 vs. -0.0161). There was some slight evidence in favour of the 
non-RUL arm with regards to having a GP home visit (Kappa= 0.335 vs. -0.0937). The 
RUL arm showed more agreement than the non-RUL arm between data sources 
in terms of number of: visits to GPs (CCC= 0.581 vs. -0.013); GP telephone calls 
(CCC= 0.564 vs. 0.173) and prescriptions (CCC= 0.418 vs. -0.13). ConClusions: 
Although based on small numbers, our study found some evidence that provision 
of an RUL reduces recall bias in relation to visits to GPs.
PRM28
systEMatiC REviEw and CRitiquE of hEalth EConoMiC ModEls on 
RElaPsing-REMitting MultiPlE sClERosis in thE uK
Kusel J.1, Maruszczak M.1, Montgomery S.1, Allen F.2, Adlard N.2
1Costello Medical Consulting Ltd., Cambridge, UK, 2Novartis Pharmaceuticals UK Limited, Surrey, 
UK
objeCtives: Several new disease modifying therapies have recently received mar-
keting authorisations for the treatment of relapsing-remitting multiple sclerosis 
(RRMS). Given the recent appraisal by NICE of these therapies, the objective of this 
study was to systematically review and critically evaluate the techniques used in 
modelling relapsing-remitting multiple sclerosis in the UK. Methods: Embase, 
Medline, Cochrane Library and the NICE website were searched systematically on 
03.03.14 to identify articles relating to cost-utility models in RRMS with a UK per-
spective. Data sources, techniques and assumptions of the included models were 
extracted, compared and critically evaluated. Results: Of 385 search results, 25 full 
texts were evaluated and 17 articles (relating to 12 different models) were included. 
Early models varied considerably in method and structure but convergence was 
apparent over time towards a Markov model with states based on disability score, 
a 1-year cycle length and a lifetime time horizon. More recent models also allowed 
for disability improvement within the natural history of the condition. Considerable 
variety remains, however, with an increasing number of comparators over time, the 
need for treatment sequencing and different assumptions around efficacy waning 
and treatment withdrawal. Additionally, modelling techniques were sometimes 
implemented inappropriately. Confidential data sources were frequently used, espe-
cially within the models submitted to NICE. ConClusions: Despite a convergence 
over recent years to a similar Markov structure, there are still significant discrep-
ancies between the models simulating the course of RRMS in the UK. Differing 
methods, assumptions and data sources make the comparison of models, and their 
results, problematic. The Markov structure commonly used also leads to problems 
such as an incapability to deal with heterogeneous populations and multiplying 
complexity with treatment sequences; these would best be solved by using alterna-
tive model types such as discrete event simulations.
PRM29
should ChangEs in dRug PRiCE ovER tiME BE ConsidEREd in Cost-
EffECtivEnEss analysEs?
Millier A.1, Briquet B.1, Aballea S.1, Toumi M.2
1Creativ-Ceutical, Paris, France, 2University of Marseille, Marseille, France
objeCtives: Cost-effectiveness analyses (CEA) are used to support funding deci-
sions for new drugs by estimating their clinical and economic value. While prices 
of drugs may fall over time due to market competition, entrance of generic drugs, 
or negotiated price cuts, this is rarely accounted for in CEA. The objective is to 
review pharmacoeconomic guidelines and current practice around drug price evalu-
ation in CEA. Methods: Pharmacoeconomic guidelines were reviewed to identify 
countries in which a drug price modification over the time horizon is allowed or 
recommended in CEA. Then methodological articles and published CEA using price 
modifications were identified. Finally, several health economics experts were inter-
viewed. Results: Only 3 pharmacoeconomic guidelines report recommendations 
around price adjustment in CEA (Norway, New-Zealand): modellers should take 
into account changes in drug price over time. In France, it is possible to include a 
generic price in sensitivity analysis. In other countries, this was not mentioned in 
the guidelines. Methodological articles mentioned the possibility to use an esti-
mated 4% decrease over time in UK. In most of published CEA incorporating price 
modifications, this was performed as secondary analyses. Other CEA reported 
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thereby providing additional information on secondary care in England. This 
study aimed to generate more accurate resource use for the management of CLL 
and iNHL by using the THIN-HES database. Methods: First, a MEDLINE and UK 
Health Technology Appraisals (HTAs) reviews were undertaken to identify stud-
ies documenting the cost of previously-treated iNHL and CLL in the UK. Then, to 
collect patients health care resource use, THIN database linked to the HES dataset 
was analysed. Results: Three HTAs were identified as relevant, and cost esti-
mates relied on assumptions from clinical experts. Assumptions varied as TA193 
related to relapsed CLL assumed that health care visits were three times more 
frequent post-progression (3 consultations/month: £86) than pre-progression (1 
consultation/month: £28.67) while another, TA202, assumed a rather constant 
number of visits across the two health states (1 clinic visit per month: £121.11). 
Therefore, analyses of the THIN database linked to HES were undertaken, includ-
ing more than 1 000 patients. OPCS4 codes and READ codes in the HES and THIN 
databases respectively, were used to identify treatments prescribed and proce-
dures undertaken. Costs were estimated by applying unit costs from national 
references. ConClusions: To our knowledge, this analysis is the first retrospec-
tive observational study to assess the cost of managing previously-treated CLL 
and iNHL in the UK. This study will serve as an important resource in the health 
economic evaluation of emerging therapies. This method suggests a greater stand-
ardization of disease management costs across HTAs.
PRM36
a systEMatiC REviEw of MEthods to assEss thE EConoMiC iMPaCt of 
aiR Pollution
Conti S., Fornari C., Madotto F., Cesana G.
University of Milano - Bicocca, Monza, Italy
objeCtives: Despite the fact that short and long-term effects of the exposure to 
air pollution on health have been extensively analyzed, estimates of the health 
care economic impact of such effects are still limited. We therefore carried out a 
systematic review of the literature, with the aim of identifying the current major 
research focuses in the field and the topics that will need to be addressed in the 
future. Methods: We searched the electronic databases MEDLINE and EMBASE, 
in which we applied respectively the following algorithms: 1) “((“cost of illness” 
[MeSH Terms] OR “health care costs” [MeSH Terms] OR “health expenditures” [MeSH 
Terms]) AND “environmental pollution” [MeSH Terms]) OR (Pollution [Title/Abstract] 
AND (Expenditure [Title/Abstract] OR Expenditures [Title/Abstract] OR cost [Title/
Abstract] OR costs [Title/Abstract]) AND (health [Title/Abstract] OR health care [Title/
Abstract]))“; 2) “‘health care cost’/exp AND ‘pollution’/exp”. Searches were limited 
to article written in English and Italian, without any date restriction. Results: 
The initial selections identified 775 records in MEDLINE and 466 in EMBASE, 149 
of which were classified as relevant. They focused on a wide range of pollutants, 
including volatile organic compounds, nitrogen dioxide, pesticides, ozone, particu-
late matter and tobacco smoke. Most of the studies assessed the health impact of 
environmental pollutants using direct and indirect cost estimates acquired from 
literature, mainly relying on cost of illness methods; 27 papers used an individual 
direct health care costs approach, but they usually didn’t involve indirect costs in 
the final computations. Finally, only a few studies distinguished between short-term 
and long-term effect of air pollution. ConClusions: The results of our review iden-
tified two main topics that deserve further research: future health impact assess-
ments should integrate indirect costs estimates with information from the direct 
modeling of real-life health care costs; the short- and long-term economic impacts 
should be clearly separated.
PRM37
Cost-EffECtivEnEss analysis of iPiliMuMaB in PREviously untREatEd 
PatiEnts with unREsECtaBlE Malignant MElanoMa in sCotland
Lee D.1, Porter J.1, Hatswell A.J.1, Hertel N.2, Walker A.3
1BresMed, Sheffield, UK, 2Bristol Myers Squibb, Uxbridge, UK, 3University of Glasgow, glasgow, 
UK
objeCtives: This analysis assessed the cost effectiveness of ipilimumab 3mg/
kg as first-line treatment for metastatic melanoma. As ipilimumab has an exist-
ing second-line recommendation, the decision problem is ipilimumab first-line 
followed by best supportive care (BSC), compared with Scottish clinical practice 
- dacarbazine or vemurafenib first-line followed by ipilimumab. Methods: In line 
with SMC requirements, an area under the curve model was built comparing first-
line ipilimumab, dacarbazine and vemurafenib. The model utilised progression, 
survival and utility data from CA184-024 for ipilimumab/dacarbazine and dacar-
bazine, survival data from MDX010-20 for ipilimumab second-line, and survival 
and progression data from BRIM-3 for vemurafenib. MDX010-20 and observational 
data, using the approved regimen, were tested within scenario analyses assessing 
the performance of ipilimumab 3mg/kg at first-line. 2013 costs were taken from 
Scottish or UK official sources. Results: Economic analysis, including patient 
access schemes for ipilimumab and vemurafenib, shows that ipilimumab first-
line followed by BSC is cost-effective versus dacarbazine first-line followed by 
ipilimumab (incremental costs: £10,502, incremental quality-adjusted life-years 
[QALYs]: 0.33, incremental cost-effectiveness ratio [ICER]: £31,481). Compared with 
ipilimumab first-line followed by BSC, the sequence vemurafenib first-line fol-
lowed by ipilimumab is associated with incremental QALYs (0.26) but also incre-
mental costs (£33,306), resulting in a not cost-effective cost/QALY trade-off (ICER 
= £126,482), i.e. ipilimumab first-line should be the preferred option. A scenario 
analysis that compared ipilimumab first-line with vemurafenib first-line alone 
resulted in ipilimumab being the dominant treatment option. Comprehensive 
sensitivity analyses identified survival parameters as having the largest impact 
on model results. Ipilimumab remained cost-effective at a threshold of £50,000 
per QALY gained against both comparators. ConClusions: First-line ipilimumab 
treatment for melanoma is cost-effective, and as a first-line option it would 
expand clinician choice, enabling selection of the most appropriate therapy for 
patients depending on their disease characteristics and BRAF mutation status.
Mauskopf et al. in 2005 and 2007. ConClusions: Based on the results we suggest the 
following definition for BIA: “A budget impact analysis is a form of health economic 
evaluation. Its purpose is to predict the financial consequences of the introduction 
or removal of an intervention from the current health care setting. Therefore BIA 
is a framework to synthesize the best available evidence. Rather than calculating 
a precise impact number it provides a valid model to the decision maker, enabling 
him to understand the relative effects of his decisions. The analysis is undertaken by 
modeling two scenarios where the reference scenario is the status quo and the second 
scenario a simulation of the decision to be made. The model parameters are chosen 
according to the framework requirement of the decision maker.”
PRM33
EPisodEs of CaRE and thEiR Costs BasEd on iCPC-2 ClassifiCation: 
thREE Month follow-uP study in finland
Heinonen J.1, Soini E.2, Ryynänen O.P.3, Koskela T.1
1Department of General Practice, University of Tampere, Tampere, Finland, 2ESiOR Oy, Kuopio, 
Finland, 3Department of Public Health and Clinical Nutrition, University of Eastern Finland, and 
General Practice Unit, Kuopio University Hospital, Kuopio, Finland
objeCtives: To explore patient characteristics, resource use and costs related to 
different episodes of care (EOC) in Finnish health care. EOC is a health problem 
needing testing, diagnosis, care or follow-up from its first presentation by the 
patient to health care until the completion of the last health care contact for 
it. Literature around costs of episodes (COE) is scarce. Methods: Primary and 
secondary care data was collected during the three months prospective, non-
randomized follow-up study (Effective Health Centre) using questionnaires and 
electronic health record. Setting included three primary health care practices in 
Pirkanmaa, Finland. 622 (41% of potential) patients were recruited during one 
week period. Patients that had doctor/nurse appointment on the recruiting day 
and agreed to participate were included. Patients visiting specialized health guid-
ance clinic for pregnant women, children and mothers were excluded. The main 
outcome measures were patient characteristics, resource use and costs classified 
based on the International Classification of Primary Care (ICPC-2) episode title 
codes. Resource use was valued with health care providers’ 2012 unit costs. Social 
Insurance Institution costs (e.g. outpatient drugs) were excluded. Results: On 
average, patient had 1.22 EOCs during the three months. Patient characteristics 
and resource use differed between the EOC-classes. Class L ‘Musculoskeletal’ had 
the highest number of episodes (17%). The most common (8%) single EOC was 
‘upper respiratory infection’. The mean COE was € 390 (SE € 61) and the median COE 
was € 165 (IQR € 118-289) during the three month follow-up. The most expensive 
class was K ‘Circulatory’, with a mean COE of € 910. The most expensive single COE 
(€ 32,546) was in the group K. The most expensive one percent of COEs summed up 
covered 36% of total COEs. ConClusions: Patient characteristics, resource use 
and costs differed between the ICPC-2 classes, which could be taken into account 
in evaluations, planning and pricing.
PRM34
do thE us PanEl RECoMMEndations hold foR EuRoPE? invEstigating 
thE RElation BEtwEEn quality of lifE vERsus woRK-status, 
aBsEntEEisM and PREsEntEEisM
Knies S.1, Boonen A.2, Severens J.L.3
1National Health Care Institute, Diemen, The Netherlands, 2Maastricht University Medical Center, 
Maastricht, The Netherlands, 3Erasmus University Rotterdam, Rotterdam, The Netherlands
objeCtives: In the last twenty years there has been an intense debate on how to 
value lost productivity in economic evaluations. According to the Washington panel, 
lost productivity influences health-related quality of life (HRQoL) and should thus 
be considered a health effect instead of a cost to avoid double counting. Until now 
empirical evidence on the inclusion of income loss when valuing health states is 
not decisive. We examine the relationship between three aspects of lost productiv-
ity (work-status, absenteeism and presenteeism) and patient or social valuation of 
health-related quality of life. Methods: Cross-sectional survey data from a total of 
830 respondents with a rheumatic disorder from four Western-European countries. 
Health-related quality of life was expressed in either the European societal utility 
using EQ-5D-3L or the patient valuation using EQ-VAS. Linear regression analyses 
were performed to examine the impact of work-status (four categories), absen-
teeism (absent from paid work during the past three months), and presenteeism 
(QQ method) on EQ-5D utilities and VAS scores taking demographic characteris-
tics and disease severity (duration, pain and restriction) into account. Results: 
The relationship between work-status, absenteeism or presenteeism and HRQoL 
is stronger for patient valuation than societal valuation. Compared to work-status 
and presenteeism is the relationship between absenteeism and HRQoL even less 
explicit. However, results for all measures of work are only marginal significant 
and negligible compared to the influence of restriction due to disease we studied.  
ConClusions: In four European countries, analyses among patients with a rheu-
matic disorder do not fully support the claim of the Washington panel that lost 
productivity has a significant relationship with HRQoL, and this is even more appar-
ent for absenteeism than for work-status and presenteeism. Therefore absenteeism 
should continue to be included in the costs and not in the QALY. Findings need to 
be confirmed in other disease areas.
PRM35
Cost of PREviously tREatEd ChRoniC lyMPhoCytiC lEuKEMia (Cll) and 
indolEnt non-hodgKin’s lyMPhoMa (inhl) in thE unitEd KingdoM (uK)
Cognet M.1, Druais S.1, Gervais F.1, Gauthier A.1, Abrams K.R.2
1Amaris, London, UK, 2University of Leicester, Leicester, UK
objeCtives: Accurate cost data are required to inform cost-effectiveness assess-
ments of novel treatments in the UK for NICE appraisals. Up to now, levels of 
resource use to manage CLL and iNHL have mainly been based on clinical expert 
opinion. However, recently, two key primary care databases in the UK (THIN and 
CPRD) were linked with Hospital Episode Statistics (HES) at the patient level, 
